Jci_page_head_homepage_01 Jci_page_head_homepage_02
Adam M. Boruchov, Glenn Heller, Maria-Concetta Veri, Ezio Bonvini, Jeffrey V. Ravetch, James W. Young
Published in Volume 115, Issue 10
J Clin Invest. 2005; 115(10):2914–2923 doi:10.1172/JCI24772
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

2B6 is a novel mAb that specifically detects an extracellular domain of CD32b. Neutrophils and PBMCs were isolated from peripheral blood samples. Cells were stained with various anti-CD32 mAbs and counterstained with anti-CD66b to define neutrophils (N) or anti-CD20 to define B cells (B). (A) mAb 2B6 detected CD32b on B cells but not CD32a on neutrophils. (B) mAb FL18.26 detected CD32a or CD32b, and it stained neutrophils as well as B cells. (C) In contrast, mAb IV.3 (Fab) detected CD32a on neutrophils but not CD32b on B cells. (D) Some mAbs were able to distinguish between the common polymorphic variants of CD32a. mAbs FL18.26 (B) and IV.3 (C) bind both the R131 and H131 subtypes of CD32a and stain neutrophils from HH homozygotes, RR homozygotes, and HR heterozygotes equally. mAbs 3D3 and 41H16 recognize only the R131 subtype (16), shown staining neutrophils from CD32a131RR individuals but not from CD32a131HH individuals, with intermediate staining of neutrophils from heterozygous (CD32a131HR [HR]) individuals.